
GPs warned over exit clauses

GPs are being warned to ensure pre-emption rights on deals are properly drafted, after recent cases highlighted potential pitfalls.
Pre-emption rights are designed to ensure that existing shareholders in a company have the right to buy a selling party's shares before they are offered elsewhere. While they are a fairly standard part of many M&A deals, poorly drafted provisions could lead to problems for GPs looking to exit a portfolio company.
Malcolm MacDougall, head of private equity at Speechly Bircham, says recent examples have highlighted the need for investors to ensure any pre-emption rights are correctly drafted and understood. These provisions are usually designed to ensure shareholders are not forced to work with a potentially objectionable third party when an existing shareholder decides to sell or to keep ownership of a company within a specified group of investors. If the provisions are poorly drafted, they can lead to unexpected delays and complications when a GP tries to exit.
"While a single GP buyout would not usually require pre-emption rights (as the GP would expect a complete restriction on transfers without its consent), this is potentially a significant issue in deals where you have a number of private equity investors, as well as in the case of co-investments and joint ventures," explains MacDougall.
Pre-emption rights are part of an ongoing dispute between the Barclay Brothers and Patrick McKillen regarding their stakes in hotel operator Coroin Ltd. There has also been a recent example of a private equity exit being delayed by a minority shareholder claiming pre-emption rights.
The main issues GPs are likely to face are objections to a sale from a small shareholder, creating delays to the sale process, or fellow investors changing without their shares first being offered to existing shareholders, as a result of the transfer of holding companies not being caught by the pre-emption provisions.
"Having seen issues surrounding pre-emption rights surface twice recently, this has the potential to be a major issue for GPs and proper drafting and understanding is vital as this can impact the ability to execute a clean exit," MacDougall warns.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater